LSB - LakeShore Biopharma Co., Ltd

LSB - LakeShore Biopharma Co., Ltd

https://www.lakeshorebio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - LakeShore Biopharma ( NASDAQ:LSB )

Benzinga • 9 months ago • score: 0.11

BEIJING, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

GlobeNewswire • 9 months ago • score: 0.11

BEIJING, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- LakeShore Biopharma Co., Ltd. ( Nasdaq: LSB ) ( "LakeShore Biopharma" or the "Company" ) , a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, ...

LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan - LakeShore Biopharma ( NASDAQ:LSB )

Benzinga • 10 months, 1 week ago • score: 0.20

GAITHERSBURG, Md., Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- LakeShore Biopharma Co., Ltd LSB ( "LakeShore Biopharma" or the "Company" ) , a global leader in the discovery, development, manufacturing, and delivery of next-generation vaccines and therapeutic biologics for infectious diseases and ...

PR Newswire • 1 year, 2 months ago • score: 0.64

LakeShore Biopharma Co., Ltd ( Nasdaq: LSB ) ( "LakeShore Biopharma" or the "Company" ) , a global biopharmaceutical company dedicated to discovering,... Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$8.60

52W Low

$0.59

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.57

Valuation

As of 2024-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-22.21

EV/Revenue (<3 favorable)

1.03

P/S (TTM) (<3 favorable)

0.06

P/B (<3 favorable)

0.50

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

77.76%

Institutions (25–75% balanced)

0.79%

Shares Outstanding

41,212,700

Float

4,712,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-03-31 (Overview)

Revenue (TTM)

614,962,000

Gross Profit (TTM)

507,189,000

EPS (TTM)

-0.73

Profit Margin (>10% good)

-0.16%

Operating Margin (TTM) (higher better)

-0.69%

ROE (TTM) (>15% strong)

-0.18%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.28

Momentum

Bearish momentum

Value

-0.0050

Previous

-0.0046

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025